AUM Biosciences Further Strengthens Advisory Board with Addition of Professor Pierce Chow
AUM Biosciences (AUM), a Singapore-based company officially announced today the addition of Professor Pierce Chow as Chairman of its Scientific Advisory Board. AUM is focused on the development of innovative and affordable oncology medicines for cancers with high unmet medical need in Asia.
About Pierce Chow
Professor Pierce Chow is Senior Consultant Surgical Oncologist and Co-Director at the Comprehensive Liver Cancer Clinic at the National Cancer Centre Singapore and Senior Consultant Surgeon at the Singapore General Hospital. He is concurrently Professor and Course Director at Duke-NUS Medical School in Singapore.
In addition to managing a busy HPB surgical oncology service, Professor Chow has researched extensively on hepatocellular carcinoma (HCC). He leads collaborative research on the genomic heterogeneity of HCC and applications in precision medicine. He co-founded the Asia-Pacific Hepatocellular Carcinoma Trials Group in 1997 and has been the protocol chair of 5 multi-national trials. In 2012 the National Medical Research Council Singapore conferred him the National Outstanding Clinician-Scientist Award for improving clinical outcomes of patients with his research on Liver Cancer.
In 2016, Professor Chow was awarded the NMRC Translational-Clinical Research Grant for the National Flagship Program in Liver Cancer and in 2017 he received funding from BMRC for the multi-institutional PuRPOSE Program to develop a patient-specific diagnostic and predictive platform to improve treatment of liver cancer.
“AUM Biosciences is privileged to have Professor Pierce Chow join our Scientific Advisory Board. His knowledge and insights in cancer therapeutics will be invaluable in helping AUM address the rising and unmet medical needs of cancer patients. We look forward to benefiting from his thought leadership,” stated Dr. Harish Dave, CMO of AUM Biosciences.
“We live in an unprecedented era of scientific advancements and the development of better therapeutics in cancer. Cancers that are more prevalent in Asia than elsewhere however still face especially challenging unmet clinical needs. We aim to accelerate the development of innovative, affordable cancer medicines for patients in Asia and around the world,” stated Professor Pierce Chow.
AUM Biosciences is an award-winning, oncology-focused biotechnology company that aims to accelerate the development of innovative, affordable cancer medicines for patients in Asia and around the world. AUM Biosciences focuses on early-stage development of innovative medicines for the treatment of Asian-prevalent cancers.
AUM Biosciences will have a specific focus on indications such as hepatocellular carcinoma, head and neck cancer, gastric cancer, cholangiocarcinoma, triple negative breast cancer, prostate and colorectal cancer. With a huge opportunity to identify targets for unmet medical needs, AUM Biosciences will partner and collaborate with leading research institutes, clinicians and pharmaceutical companies bringing new, affordable and effective therapies to patients in need.